Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd ( (AU:IMM) ) has provided an update.
Immutep has discontinued its pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer after an interim futility analysis showed the eftilagimod alfa combination arm underperformed the control arm, prompting an orderly wind-down and a comprehensive root cause analysis that may extend into the third quarter of 2026. Despite this setback, the company continues to advance other efti programs, including the INSIGHT-003 lung cancer study and the EFTISARC-NEO soft tissue sarcoma trial, which met its primary objective and secured U.S. orphan drug designation, while early-stage autoimmune candidate IMP761 has shown a favorable safety profile, all supported by a strong A$110.6 million cash position expected to fund operations into the first half of 2028.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa, is being tested in combination with standard treatments such as checkpoint inhibitors and chemotherapy, while another asset, IMP761, targets autoimmune indications. The company partners with industry players including Dr. Reddy’s Laboratories to advance its pipeline globally.
Average Trading Volume: 41,079,770
Technical Sentiment Signal: Sell
Current Market Cap: A$104.6M
See more insights into IMM stock on TipRanks’ Stock Analysis page.